Medication Adherence of Tamoxifen to Breast Cancer Patients and the Affecting’s Factors in Dharmais Cancer Hospital Jakarta
DOI:
https://doi.org/10.18196/jmmr.92120Keywords:
Breast cancer, Medication Adherence, TamoxifenAbstract
Several previous studies show that adherence to hormonal therapy increases the survival rate in Breast Cancer (BC) with ER+ or PR+. Tamoxifen is one of oral chemotherapy which is the most used hormonal therapy in breast cancer treatment regimens. The focus of the study was to determine the level of adherence and factors influencing the adherence of the treatment of BC patients undergoing hormonal therapy with Tamoxifen in patients at Dharmais Cancer Hospital in the year 2018. The study is an observational study with a cross-sectional design. The study was followed by 109 respondents. Medication adherence levels assessed via questionnaire modified MARS-5. Sociodemographic and clinical characteristics obtained from interviews using structured questionnaires. Medication adherence’s level of Tamoxifen was 90.9% with the proportion of adhering patients was 75.2% (82 of 109 patients). Multivariate analysis showed that the age of respondents, level of education, level of knowledge is the most influential factor and determine the level of treatment adherence. Education level is the variable that has the greatest effect on medication adherence. Through this study, it is recommended to pay more attention to patients with specific characteristics such as patients with low education and or low income.
References
Wigertz A, Ahlgren J, Holmqvist M. Compliance and Discontinuation of Adjuvant Hormonal Therapy in Breast Cancer Patients : A Population-Based Study.2012:367-373. doi:10.1007/s10549-012-1961-4.
Kementerian Kesehatan RI. Situasi Penyakit Kanker di Indonesia. Pusat Data dan Informasi Kesehatan infodatin-Kanker. 2015:hal 3.
Mccowan, C., Shearer, J., Donnan, P. T., Dewar, J. A., Crilly, M., Thompson, A. M., & Fahey, T. P. Cohort study examining tamoxifen compliance and its relationship to mortality in women with breast cancer. British Journal of Cancer, 99, 2008: 1763–1768. doi:10.1038/sj.bjc.6604758
Grunfeld, E. A., Hunter, M. S., Sikka, P., & Mittal, S. Compliance beliefs among breast cancer patients taking tamoxifen, Patient Education and Counselings. 2005; 59(1):97-102.doi: 10.1016/j.pec.2004.10.005
Budiman A, Khambri D, Bachtiar H. Faktor Yang Mempengaruhi Kepatuhan Berobat Pasien Yang Diterapi Dengan Tamoxifen Setelah Operasi Kanker Payudara. 2013;2(1):20-24.
Hsieh, K., Chen, L., Cheung, K., & Yang, Y. (2015). Risks of noncompliance to hormone therapy in Asian women with breast cancer. Kaohsiung Journal of Medical Sciences, 2015;31(6), 328–334. doi:10.1016/j.kjms.2015.04.002
Ali EE, Cheung KL, Lee CP, Leow JL, Yap KY, Chew L. Prevalence and Determinants of Compliance to Oral Adjuvant Endocrine Therapy among Breast Cancer Patients in Singapore. Asia-Pacific Journal of Oncology Nursing. 2017:283-289. doi:10.4103/2347-5625.212864.
Peng M-T, Chen S-C, Shen W-C, Lin Y-C, Chang H-K. The Compliance and Tolerance of Adjuvant Endocrine Therapy in Geriatric Breast Cancer Patients. J Cancer Res Pract. 2016;3(3):69-72. doi:10.1016/j.jcrpr.2016.05.002.
Barron TI, Bennett K, Feely J, Kennedy MJ. Early Discontinuation of Tamoxifen A Lesson for Oncologists. Cancer. 2007;(January):832-839. doi:10.1002/cncr.22485.
Bender, C. M., Gentry, A. L., Brufsky, A. M., Casillo, F. E., Cohen, S. M., Meredith, M., Dunbar-jacob J. Influence of Patient and Treatment Factors on Compliance to Adjuvant Endocrine Therapy in Breast Cancer. Oncol Nurs Forum. 2014;3:274-285. doi:10.1188/14.ONF.274-285.
Jimmy B, Jose J. Patient Medication compliance: Measures in Daily Practice. Oman Medical Journal. 2011;26(3):155-159.
Murphy CC, Bartholomew LK, Carpentier MY, Bluethmann SM, Vernon SW. Compliance to adjuvant hormonal therapy among breast cancer survivors in clinical practice : a systematic review.Breast Cancer Research Treatment. 2012:459-478. doi:10.1007/s10549-012-2114-5.
Herk-Sukel MPP van, Poll-Franse LV van de, Voogd AC, Nieuwenhuijzen GAP, Coebergh JWW, Hering RMC. Half of Breast Cancer Patients Discontinue Tamoxifen and Any Endocrine Treatment Before the End of The Recommended Treatment Period Of 5 Years : A Population-Based Analysis. Breast Cancer Research Treatment. 2010:843-851. doi:10.1007/s10549-009-0724-3.
Gotay C. Compliance to Long-Term Adjuvant Hormonal Therapy for Breast Cancer. Expert Rev. Pharmacoeconomics Outcomes Res. 11(6), 2011. doi: 10.1586/ERP.11.80
Moon Z, Moss-morris R, Hunter MS, Hughes LD. More than just side-effects : The role of clinical and psychosocial factors in non-compliance to tamoxifen. British Journal of Health Psychology. 2017:998-1018. doi:10.1111/bjhp.12274.
Nguyen T, Caze A La, Cottrell N. What are Validated Self-Report Compliance Scales Really Measuring ? A Systematic Review.Br J Clin Pharmacol.1999. doi:10.1111/bcp.12194.
Ganz PA. Improving Outcomes for Breast Cancer Survivors. Los Angeles: Springer Healthcare; 2015.
Hess LM, Raebel MA, Conner DA, Malone DC. Measurement of Compliance in Pharmacy Administrative Databases : A Proposal for Standard Definitions and Preferred Measures. Ann Pharmacother. 2006;40:1280-1288. doi:10.1345/aph.1H018.
Kardas P, Lewek P, Matyjaszczyk M. Determinants of Patient Compliance : A Review of Systematic Reviews. Front Pharmacol.2013;4(July):1-16. doi:10.3389/fphar.2013.00091.
Weaver KE, Camacho F, Hwang W, Anderson R, Kimmick G. Compliance to Adjuvant Hormonal Therapy and Its Relationship to Breast Cancer Recurrence and Survival Among Low Income Women. American Journal of Oncology. 2014;36(2), 181–187. doi:10.1097/COC.0b013e3182436ec1.
Wu J, Lu ZK. Hormone Therapy Adherence and Costs in Women With Breast Cancer. Am J Pharm Benefits. 2013;5(2):65–70.
Sinaga ES, Ahmad RA, Hutajulu SH. Ketahanan Hidup 5 tahun pada Pasien Kanker Payudara. Berita Kedokteran Masyarakat.;33(2):67-72
Downloads
Published
Issue
Section
License
Copyright (c) 2020 JMMR (Jurnal Medicoeticolegal dan Manajemen Rumah Sakit)
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
